2004
DOI: 10.1016/j.bbcan.2004.05.002
|View full text |Cite
|
Sign up to set email alerts
|

RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis

Abstract: The emergence of the molecular triad osteoprotegerin (OPG)/Receptor Activator of NF-kB (RANK)/RANK Ligand (RANKL) has helped elucidate a key signalling pathway between stromal cells and osteoclasts. The interaction between RANK and RANKL plays a critical role in promoting osteoclast differentiation and activation leading to bone resorption. OPG is a soluble decoy receptor for RANKL that blocks osteoclast formation by inhibiting RANKL binding to RANK. The OPG/RANK/RANKL system has been shown to be abnormally re… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
178
0
3

Year Published

2005
2005
2020
2020

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 144 publications
(182 citation statements)
references
References 59 publications
1
178
0
3
Order By: Relevance
“…Some of these recent studies are concerned with designing effective and rational drugs to treat bone-related diseases [21][22][23]. After all, osteoclastogenesis/bone resorption in periodontal disease can be ameliorated by inhibition of RANKL activity or by diminishing immune cell stimulation.…”
Section: Discussionmentioning
confidence: 99%
“…Some of these recent studies are concerned with designing effective and rational drugs to treat bone-related diseases [21][22][23]. After all, osteoclastogenesis/bone resorption in periodontal disease can be ameliorated by inhibition of RANKL activity or by diminishing immune cell stimulation.…”
Section: Discussionmentioning
confidence: 99%
“…One of the therapeutic strategies developed to block pathological osteoclast differentiation in cancer is therefore to block RANK signaling. 58 …”
Section: Nf-jb In Cancermentioning
confidence: 99%
“…Previously, it was reported that N-BPs may also exhibit direct effects on osteoblast cells by altering the expression of receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin (OPG) (10). OPG is a soluble decoy receptor for RANKL that blocks osteoclast formation by inhibiting the binding of RANKL to the receptor activator of nuclear factor-κB (RANK) (8,9).…”
Section: Introductionmentioning
confidence: 99%